Biomarker Potential Of Egfr Gene Copy Number By Fish In The Phase Iii Extreme Study: Platinum-Based Ct Plus Cetuximab In First-Line R/M Scchn

L. Licitra, F. Rolland, C. Bokemeyer, E. Remenar, H. Kienzer, S. Stoerkel, S. Scheid,C. Stroh, R. Mesia

JOURNAL OF CLINICAL ONCOLOGY（2009）

引用 20|浏览0

暂无评分

摘要

6005 Background: Platinum-based CT + cetuximab is the first systemic therapy in ∼30 years to show a survival benefit vs platinum-based CT in first-line R/M SCCHN (Vermorken JB, et al. N Engl J Med ...

查看译文

关键词

Cetuximab,Biomarker (medicine),Oncology,Copy-number variation,Bioinformatics,Platinum,Medicine,First line,Internal medicine,Survival benefit

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要